The estimated Net Worth of Gianfranco Nazzi is at least $4.71 Milion dollars as of 3 March 2021. Mr. Nazzi owns over 1,400 units of Teva- Pharmaceutical Industries stock worth over $25,144 and over the last 7 years he sold TEVA stock worth over $1,233,680. In addition, he makes $3,449,170 as Executive Vice President - International Markets Commercial at Teva- Pharmaceutical Industries.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Nazzi TEVA stock SEC Form 4 insiders trading
Gianfranco has made over 8 trades of the Teva- Pharmaceutical Industries stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 12,935 units of TEVA stock worth $136,852 on 4 March 2021.
The largest trade he's ever made was selling 75,587 units of Teva- Pharmaceutical Industries stock on 28 February 2021 worth over $821,631. On average, Gianfranco trades about 7,134 units every 30 days since 2018. As of 3 March 2021 he still owns at least 1,400 units of Teva- Pharmaceutical Industries stock.
You can see the complete history of Mr. Nazzi stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Gianfranco Nazzi biography
Gianfranco Nazzi serves as Executive Vice President - International Markets Commercial of the Company. He served as President and CEO of International Markets, Global Generic Medicines Group. Mr. Nazzi joined Teva as Senior Vice President, Specialty Medicines Europe in 2014. Prior to joining Teva, he served seven years at AstraZeneca in various senior roles, including Sales and Marketing Vice President Europe, Global Vice President Respiratory, General Manager of the Balkans and Vice President Primary Care in Italy. Prior to that, he served for two years as BU Director Metabolic & Cardiovascular at GlaxoSmithKline and five years in various sales and marketing roles at Eli Lilly and Company in both Italy and the United States. Mr. Nazzi received his BA degree in economics from the University of Udine, and his master’s degree in management studies from SDA Bocconi.
What is the salary of Gianfranco Nazzi?
As the Executive Vice President - International Markets Commercial of Teva- Pharmaceutical Industries, the total compensation of Gianfranco Nazzi at Teva- Pharmaceutical Industries is $3,449,170. There are 5 executives at Teva- Pharmaceutical Industries getting paid more, with Kaare Schultz having the highest compensation of $11,596,600.
How old is Gianfranco Nazzi?
Gianfranco Nazzi is 51, he's been the Executive Vice President - International Markets Commercial of Teva- Pharmaceutical Industries since 2017. There are 20 older and 7 younger executives at Teva- Pharmaceutical Industries. The oldest executive at Teva- Pharmaceutical Industries Ltd. is Gerald Lieberman, 73, who is the Independent Director.
What's Gianfranco Nazzi's mailing address?
Gianfranco's mailing address filed with the SEC is C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 5 BASEL STREET, PETACH TIKVA, L3, 4951033.
Insiders trading at Teva- Pharmaceutical Industries
Over the last 7 years, insiders at Teva- Pharmaceutical Industries have traded over $31,332,399 worth of Teva- Pharmaceutical Industries stock and bought 967,500 units worth $16,473,820 . The most active insiders traders include Sol J Barer, Tal Zvi Zaks a Roberto Mignone. On average, Teva- Pharmaceutical Industries executives and independent directors trade stock every 9 days with the average trade being worth of $636,538. The most recent stock trade was executed by Varda Shalev on 2 September 2024, trading 12,872 units of TEVA stock currently worth $231,181.
What does Teva- Pharmaceutical Industries do?
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.
What does Teva- Pharmaceutical Industries's logo look like?
Complete history of Mr. Nazzi stock trades at Teva- Pharmaceutical Industries
Teva- Pharmaceutical Industries executives and stock owners
Teva- Pharmaceutical Industries executives and other stock owners filed with the SEC include:
-
Kaare Schultz,
President, Chief Executive Officer, Director -
Kare Schultz,
Pres, CEO & Director -
Mark Sabag,
Executive Vice President, Chief Human Resources Officer and Global Communications and Brand -
Hafrun Fridriksdottir,
Executive Vice President - Global R&D -
Brendan O'Grady,
Executive Vice President - North America Commercial -
Gianfranco Nazzi,
Executive Vice President - International Markets Commercial -
Dr. Hafrun Fridriksdottir,
Exec. VP of Global R&D -
Gianfranco Nazzi,
Exec. VP of International Markets Commercial -
Eric Drape,
Exec. VP of Global Operations -
Eliyahu Sharon Kalif,
Exec. VP & CFO -
Sol Barer,
Independent Chairman of the Board -
Nechemia Peres,
Independent Director -
Gerald Lieberman,
Independent Director -
Amir Elstein,
Independent Director -
Roberto Mignone,
Independent Director -
Rosemary Crane,
Independent Director -
Jean-Michel Halfon,
Independent Director -
Perry Nisen,
Independent Director -
Ronit Satchi-Fainaro,
Independent Director -
Eliyahu Kalif,
Chief Financial Officer, Executive Vice President -
Kevin Mannix,
Senior Vice President, Investor Relations -
Janet Vergis,
Independent Director -
Abbas Hussain,
Independent Director -
David Stark,
Executive Vice President, Chief Legal Officer -
Eric Drape,
Executive Vice President - Global Operations -
Sven Dethlefs,
Executive Vice President - Global Marketing & Portfolio -
Richard Daniell,
Executive Vice President - European Commercial -
Eli Shani,
Exec. VP of Global Marketing & Portfolio -
Galia Inbar,
Exec. VP, Chief HR Officer and Head of Global Communications, Brand & ESG -
David M. Stark,
Exec. VP & Chief Legal Officer -
Amir Weiss,
Sr. VP & Chief Accounting Officer -
Lori Queisser,
Sr. VP & Global Compliance Officer -
Andrew J. Weil CPA,
Chief Accounting Officer -
Eric Drapé,
Exec. VP of Global Operations -
Iris Beck Codner,
EVP Global Brand&Communication -
Kare Schultz,
President and CEO -
Michael James Mc Clellan,
EVP, Chief Financial Officer -
Notaristefani Carlo De,
Executive VP Global Operations -
Placid Jover,
See "Remarks" -
Deborah A Griffin,
Chief Accounting Officer -
Varda Shalev,
-
Dan S Suesskind,
Director -
Murray A Goldberg,
Director -
Dov Bergwerk,
Acting Chief Legal Officer -
David R. Mc Avoy,
EVP, Chief Legal Officer -
Andrew Weil,
Chief Accounting Officer -
Galia Inbar,
See "Remarks" -
Eli Shani,
EVP,Global Marketing&Portfolio -
Angus Grant,
EVP, Business Development -
Eric A Hughes,
See "Remarks" -
Vikki L Conway,
See "Remarks" -
Christine Fox,
EVP, Head of U.S. Commercial -
Amir Weiss,
Chief Accounting Officer -
Richard D Francis,
President and CEO -
Matthew Shields,
EVP, Global Operations -
Tal Zvi Zaks,